Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16250667rdf:typepubmed:Citationlld:pubmed
pubmed-article:16250667lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C0022104lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C0295352lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C0728938lld:lifeskim
pubmed-article:16250667lifeskim:mentionsumls-concept:C1527240lld:lifeskim
pubmed-article:16250667pubmed:issue22lld:pubmed
pubmed-article:16250667pubmed:dateCreated2005-10-27lld:pubmed
pubmed-article:16250667pubmed:abstractTextDuring our search for therapeutic agents to treat diarrhea-predominant IBS, we found that 2-substituted benzoxazole derivatives have a characteristic 5-HT(3) receptor partial agonist activity with high affinity. Some of these compounds showed high in vitro metabolical stability, and 6g showed marked antidiarrhetic activity with little side effect of constipation in in vivo tests. Our results indicate that 5-HT(3) receptor partial agonists might be superior as therapeutic agents to the drugs currently used for IBS treatment.lld:pubmed
pubmed-article:16250667pubmed:languageenglld:pubmed
pubmed-article:16250667pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250667pubmed:citationSubsetIMlld:pubmed
pubmed-article:16250667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250667pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16250667pubmed:statusMEDLINElld:pubmed
pubmed-article:16250667pubmed:monthNovlld:pubmed
pubmed-article:16250667pubmed:issn0022-2623lld:pubmed
pubmed-article:16250667pubmed:authorpubmed-author:MurakamiHiros...lld:pubmed
pubmed-article:16250667pubmed:authorpubmed-author:SuzukiHisashi...lld:pubmed
pubmed-article:16250667pubmed:authorpubmed-author:ItoTomokoTlld:pubmed
pubmed-article:16250667pubmed:authorpubmed-author:KawanoKen-ich...lld:pubmed
pubmed-article:16250667pubmed:authorpubmed-author:YoshidaSatosh...lld:pubmed
pubmed-article:16250667pubmed:authorpubmed-author:SatoYasuoYlld:pubmed
pubmed-article:16250667pubmed:authorpubmed-author:ShiokawaSojir...lld:pubmed
pubmed-article:16250667pubmed:issnTypePrintlld:pubmed
pubmed-article:16250667pubmed:day3lld:pubmed
pubmed-article:16250667pubmed:volume48lld:pubmed
pubmed-article:16250667pubmed:ownerNLMlld:pubmed
pubmed-article:16250667pubmed:authorsCompleteYlld:pubmed
pubmed-article:16250667pubmed:pagination7075-9lld:pubmed
pubmed-article:16250667pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:meshHeadingpubmed-meshheading:16250667...lld:pubmed
pubmed-article:16250667pubmed:year2005lld:pubmed
pubmed-article:16250667pubmed:articleTitleOrally active benzoxazole derivative as 5-HT3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome.lld:pubmed
pubmed-article:16250667pubmed:affiliationPharmaceutical Research Department, Meiji Seika Kaisha, Ltd., 760 Morooka-Cho, Kohoku-ku, Yokohama 222-8567, Japan. satoshi_yoshida@meiji.co.jplld:pubmed
pubmed-article:16250667pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16250667pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16250667lld:pubmed